Kyverna Therapeutics

KYTXNASDAQExtreme Risk

Engineered CD19-targeted chimeric antigen receptor (CAR) T-cell therapies designed to reset the immune system by depleting pathogenic B cells in autoimmune diseases.

Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

Cell & Gene Therapy Autoimmune Diseases

Market cap

Small cap

Cash position

$250M as of Q1 2025

~25 months runway (derived)

Revenue status

pre revenue

Pipeline assets

10 programs

Trade KYTX commission-free on Webullvia Webull · Affiliate

What does Kyverna Therapeutics do?

Kyverna Therapeutics is a biotech company that is trying to use a powerful cancer treatment to fight autoimmune diseases. Normally, our immune system protects us, but in autoimmune diseases it mistakenly attacks our own body. Kyverna takes a patient's own immune cells (T cells), engineers them to find and destroy a type of B cell that is causing the trouble, and then infuses them back. This is like a 'reset' for the immune system. The company is testing this approach in diseases like lupus, multiple sclerosis, and rheumatoid arthritis. For investors, the potential is huge because these are chronic diseases affecting millions, and a one-time treatment could be curative. However, this is very early-stage science. Many trials have been stopped early, which is a red flag. The company is also spending a lot of money without any revenue. The key question is whether the treatment works safely and lasts. If it does, Kyverna could be a game-changer, but if not, the stock could be worthless. Investors should watch for data from ongoing trials and any news about manufacturing or safety.

What to watch

Monitor announcements of data from the completed Stiff Person Syndrome trial and any updates on the terminated lupus trials.

Track patient enrollment and any changes to the ongoing phase 2 myasthenia gravis trial.

Watch for updates on manufacturing scale-up and cost reduction initiatives.

Follow presentations at major conferences like ASGCT or ISCT for updated efficacy and safety data.

Keep an eye on cash burn and any financing activities that could dilute shareholders.

Pipeline

Drug	Indication	Phase	Expected data
KYV-101	Systemic Sclerosis	Phase 1	Q4 2025	▼
KYV-101	Lupus Nephritis	Phase 1	Q4 2025	▼
KYV-101	Lupus Nephritis (Refractory)	Phase 1	Q4 2025	▼
KYV-101	Progressive Multiple Sclerosis	Phase 1	Q2 2026	▼
KYV-101	Generalized Myasthenia Gravis	Phase 2	Q2 2026	▼
KYV-101	Stiff Person Syndrome	Phase 2	Q3 2025	▼
KYV-101	Rheumatoid Arthritis	Phase 1	Q4 2025	▼
KYV-101	Multiple Sclerosis (Non-relapsing and Progressive)	Phase 1	Q2 2026	▼
KYV-101	Autoimmune Diseases (Multiple)	Phase 1	Q4 2025	▼
KYV-101	Long-term Follow-up	NDA/BLA Filed	Ongoing	▼

Investment thesis

Bull case

Kyverna is pioneering CAR T therapy for autoimmune diseases, a potentially curative approach for millions of patients. Unlike oncology, autoimmune diseases are chronic and often affect younger patients, creating a large market. The company's lead asset, KYV-101, has shown promising early data in lupus nephritis and other indications, with a manageable safety profile. If the platform works across multiple diseases, Kyverna could become a leader in a new class of medicines. With a strong cash position and multiple ongoing trials, the company has multiple shots on goal. The recent completion of a phase 2 trial in Stiff Person Syndrome and ongoing phase 2 in myasthenia gravis could provide near-term catalysts. If durability of response is confirmed, Kyverna could command premium pricing and significant market share.

Bear case

Kyverna faces significant challenges. Manufacturing CAR T cells is complex and expensive, leading to high costs and potential pricing hurdles. The durability of response is unproven; patients may relapse after initial improvement. Several trials have been terminated, raising concerns about execution and data quality. The company is pre-revenue and burning cash rapidly, requiring future dilution. Competition is intense, with larger players like Novartis and Cabaletta also developing CAR T therapies for autoimmune diseases. Regulatory hurdles are high, and safety concerns like cytokine release syndrome and neurotoxicity remain. If early data fail to replicate or durability is poor, the stock could plummet. Additionally, the company's focus on rare autoimmune diseases may limit market size compared to oncology.